|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dawson MA, Prinjha RK, Dittmann A,
Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C,
Savitski MM, et al: Inhibition of BET recruitment to chromatin as
an effective treatment for MLL-fusion leukaemia. Nature.
478:529–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andrieu G, Tran AH, Strissel KJ and Denis
GV: BRD4 regulates breast cancer dissemination through
Jagged1/Notch1 signaling. Cancer Res. 76:6555–6567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Papavassiliou KA and Papavassiliou AG:
Bromodomains: Pockets with therapeutic potential. Trends Mol Med.
20:477–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filippakopoulos P and Knapp S: Targeting
bromodomains: Epigenetic readers of lysine acetylation. Nat Rev
Drug Discov. 13:337–356. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dhalluin C, Carlson JE, Zeng L, He C,
Aggarwal AK and Zhou MM: Structure and ligand of a histone
acetyltransferase bromodomain. Nature. 399:491–496. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jang MK, Mochizuki K, Zhou M, Jeong HS,
Brady JN and Ozato K: The bromodomain protein Brd4 is a positive
regulatory component of P-TEFb and stimulates RNA polymerase
II-dependent transcription. Mol Cell. 19:523–534. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng L and Zhou MM: Bromodomain: An
acetyl-lysine binding domain. FEBS Lett. 513:124–128. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Segura MF, Fontanals-Cirera B,
Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez
P, Morante M, Jubierre L, Zhang W, et al: BRD4 sustains melanoma
proliferation and represents a new target for epigenetic therapy.
Cancer Res. 73:6264–6276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lockwood WW, Zejnullahu K, Bradner JE and
Varmus H: Sensitivity of human lung adenocarcinoma cell lines to
targeted inhibition of BET epigenetic signaling proteins. Proc Natl
Acad Sci USA. 109:19408–19413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Delmore JE, Issa GC, Lemieux ME, Rahl PB,
Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et
al: BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zuber J, Shi J, Wang E, Rappaport AR,
Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al:
RNAi screen identifies Brd4 as a therapeutic target in acute
myeloid leukaemia. Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahl PB, Lin CY, Seila AC, Flynn RA,
McCuine S, Burge CB, Sharp PA and Young RA: c-Myc regulates
transcriptional pause release. Cell. 141:432–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce
LA, Thompson RC, Muller S, Knapp S and Wang J: Inhibition of BET
bromodomain targets genetically diverse glioblastoma. Clin Cancer
Res. 19:1748–1759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Ma P, Jing Y, Yan Y, Cai MC,
Zhang M, Zhang S, Peng H, Ji ZL, Di W, et al: BET Bromodomain
inhibition as a therapeutic strategy in ovarian cancer by
downregulating FoxM1. Theranostics. 6:219–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu
JJ and Ding JY: High level of BRD4 promotes non-small cell lung
cancer progression. Oncotarget. 7:9491–9500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y,
Cao X, Ling EA and Hao A: Oct4 is expressed in human gliomas and
promotes colony formation in glioma cells. Glia. 57:724–733. 2009.
View Article : Google Scholar
|
|
18
|
Azim HA Jr, Peccatori FA, Brohée S,
Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G and
Sotiriou C: RANK-ligand (RANKL) expression in young breast cancer
patients and during pregnancy. Breast Cancer Res. 17:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeo W, Chan SL, Mo FK, Chu CM, Hui JW,
Tong JH, Chan AW, Koh J, Hui EP, Loong H, et al: Phase I/II study
of temsirolimus for patients with unresectable Hepatocellular
Carcinoma (HCC)-a correlative study to explore potential biomarkers
for response. BMC Cancer. 15:3952015. View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Saldanha AJ: Java Treeview - extensible
visualization of microarray data. Bioinformatics. 20:3246–3248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Asangani IA, Dommeti VL, Wang X, Malik R,
Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S,
Engelke C, et al: Therapeutic targeting of BET bromodomain proteins
in castration-resistant prostate cancer. Nature. 510:278–282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bandopadhayay P, Bergthold G, Nguyen B,
Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R,
Masoud S, et al: BET bromodomain inhibition of MYC-amplified
medulloblastoma. Clin Cancer Res. 20:912–925. 2014. View Article : Google Scholar
|
|
24
|
Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang
Q, Lin Y, Li J, Kang T, Tao M, et al: Disrupting the interaction of
BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like
breast cancer. Cancer Cell. 25:210–225. 2014. View Article : Google Scholar :
|
|
25
|
Whyte WA, Orlando DA, Hnisz D, Abraham BJ,
Lin CY, Kagey MH, Rahl PB, Lee TI and Young RA: Master
transcription factors and mediator establish super-enhancers at key
cell identity genes. Cell. 153:307–319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pastori C, Daniel M, Penas C, Volmar CH,
Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar
RJ, et al: BET bromodomain proteins are required for glioblastoma
cell proliferation. Epigenetics. 9:611–620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dawson MA, Kouzarides T and Huntly BJP:
Targeting epigenetic readers in cancer. N Engl J Med. 367:647–657.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Muller S, Filippakopoulos P and Knapp S:
Bromodomains as therapeutic targets. Expert Rev Mol Med.
13:e292011. View Article : Google Scholar :
|
|
29
|
Belkina AC and Denis GV: BET domain
co-regulators in obesity, inflammation and cancer. Nat Rev Cancer.
12:465–477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dey A, Ellenberg J, Farina A, Coleman AE,
Maruyama T, Sciortino S, Lippincott-Schwartz J and Ozato K: A
bromodomain protein, MCAP, associates with mitotic chromosomes and
affects G(2)-to-M transition. Mol Cell Biol. 20:6537–6549. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dey A, Chitsaz F, Abbasi A, Misteli T and
Ozato K: The double bromodomain protein Brd4 binds to acetylated
chromatin during interphase and mitosis. Proc Natl Acad Sci USA.
100:8758–8763. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu TY, Simon LM, Neill NJ, Marcotte R,
Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, et al:
The spliceosome is a therapeutic vulnerability in MYC-driven
cancer. Nature. 525:384–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hahn CN, Venugopal P, Scott HS and Hiwase
DK: Splice factor mutations and alternative splicing as drivers of
hematopoietic malignancy. Immunol Rev. 263:257–278. 2015.
View Article : Google Scholar
|
|
34
|
Wojtuszkiewicz A, Assaraf YG, Maas MJ,
Kaspers GJ, Jansen G and Cloos J: Pre-mRNA splicing in cancer: The
relevance in oncogenesis, treatment and drug resistance. Expert
Opin Drug Metab Toxicol. 11:673–689. 2015. View Article : Google Scholar
|
|
35
|
Coomans de Brachène A and Demoulin JB:
FOXO transcription factors in cancer development and therapy. Cell
Mol Life Sci. 73:1159–1172. 2016. View Article : Google Scholar
|
|
36
|
Powathil GG, Gordon KE, Hill LA and
Chaplain MA: Modelling the effects of cell-cycle heterogeneity on
the response of a solid tumour to chemotherapy: Biological insights
from a hybrid multiscale cellular automaton model. J Theor Biol.
308:1–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hallett RM, Huang C, Motazedian A, Auf der
Mauer S, Pond GR, Hassell JA, Nordon RE and Draper JS:
Treatment-induced cell cycle kinetics dictate tumor response to
chemotherapy. Oncotarget. 6:7040–7052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koval A, Ahmed K and Katanaev VL:
Inhibition of Wnt signalling and breast tumour growth by the
multi-purpose drug suramin through suppression of heterotrimeric G
proteins and Wnt endocytosis. Biochem J. 473:371–381. 2016.
View Article : Google Scholar
|
|
39
|
Leek RD, Stratford I and Harris AL: The
role of hypoxia-inducible factor-1 in three-dimensional tumor
growth, apoptosis, and regulation by the insulin-signaling pathway.
Cancer Res. 65:4147–4152. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sawa M, Masuda M and Yamada T: Targeting
the Wnt signaling pathway in colorectal cancer. Expert Opin Ther
Targets. 20:419–429. 2016. View Article : Google Scholar
|
|
41
|
Ramos-Solano M, Álvarez-Zavala M,
García-Castro B, Jave-Suárez LF and Aguilar-Lemarroy A: Wnt
signalling pathway and cervical cancer. Rev Med Inst Mex Seguro
Soc. 53(Suppl 2): S218–S224. 2015.In Spanish.
|
|
42
|
Yong X, Tang B, Xiao YF, Xie R, Qin Y, Luo
G, Hu CJ, Dong H and Yang SM: Helicobacter pylori upregulates Nanog
and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem
cell-like properties in human gastric cancer. Cancer Lett.
374:292–303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang L, Tang H, Kong Y, Xie X, Chen J,
Song C, Liu X, Ye F, Li N, Wang N, et al: LGR5 Promotes Breast
Cancer Progression and Maintains Stem-Like Cells Through Activation
of Wnt/β-Catenin Signaling. Stem Cells. 33:2913–2924. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhi X, Lin L, Yang S, Bhuvaneshwar K, Wang
H, Gusev Y, Lee MH, Kallakury B, Shivapurkar N, Cahn K, et al:
βII-Spectrin (SPTBN1) suppresses progression of hepatocellular
carcinoma and Wnt signaling by regulation of Wnt inhibitor
kallistatin. Hepatology. 61:598–612. 2015. View Article : Google Scholar :
|
|
45
|
Zhang N, Wei P, Gong A, Chiu WT, Lee HT,
Colman H, Huang H, Xue J, Liu M, Wang Y, et al: FoxM1 promotes
β-catenin nuclear localization and controls Wnt target-gene
expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zheng H, Ying H, Wiedemeyer R, Yan H,
Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, et al:
LAGL2 regulates Wnt signaling to impede differentiation in neural
stem cells and gliomas. Cancer Cell. 17:497–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jiang X, Yu Y, Yang HW, Agar NY, Frado L
and Johnson MD: The imprinted gene PEG3 inhibits Wnt signaling and
regulates glioma growth. J Biol Chem. 285:8472–8480. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ryu MJ, Liu Y, Zhong X, Du J, Peterson N,
Kong G, Li H, Wang J, Salamat S, Chang Q, et al: Oncogenic Kras
expression in post-mitotic neurons leads to S100A8-S100A9 protein
overexpression and gliosis. J Biol Chem. 287:22948–22958. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Milinkovic VP, Skender Gazibara MK,
Manojlovic Gacic EM, Gazibara TM and Tanic NT: The impact of TP53
and RAS mutations on cerebellar glioblastomas. Exp Mol Pathol.
97:202–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee DH, Qi J, Bradner JE, Said JW, Doan
NB, Forscher C, Yang H and Koeffler HP: Synergistic effect of JQ1
and rapamycin for treatment of human osteosarcoma. Int J Cancer.
136:2055–2064. 2015. View Article : Google Scholar
|
|
51
|
Chapuy B, McKeown MR, Lin CY, Monti S,
Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al:
Discovery and characterization of super-enhancer-associated
dependencies in diffuse large B cell lymphoma. Cancer Cell.
24:777–790. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mertz JA, Conery AR, Bryant BM, Sandy P,
Balasubramanian S, Mele DA, Bergeron L and Sims RJ III: Targeting
MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl
Acad Sci USA. 108:16669–16674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu X, Zhang Y, Chen Y, Li M, Zhou F, Li
K, Cao H, Ni M, Liu Y, Gu Z, et al: In situ capture of chromatin
interactions by biotinylated dCas9. Cell. 170:1028–1043.e19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang W, Prakash C, Sum C, Gong Y, Li Y,
Kwok JJ, Thiessen N, Pettersson S, Jones SJ, Knapp S, et al:
Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II
serine 2 phosphorylation in human CD4+ T cells. J Biol
Chem. 287:43137–43155. 2012. View Article : Google Scholar : PubMed/NCBI
|
